ATF3

Across TCGA pan-cancer cohorts, ATF3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATF3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATF3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATF3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where ATF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.423	1.000	.036	8	view →
LSCC	OS	Tertile	II,III,IV	0.926	1.000	.034	2	view →
PDAC	OS	Tertile	II,III,IV	1.000	0.675	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATF3–HNSC (DFS)

Open the HNSC breakdown →